Other languages Pieris Pharmaceuticals, Inc.

Equities

PIRS

US7207952026

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
11.72 ^USD	+1.03%		+1.03%	-19.51%

Apr. 19	Pieris Pharmaceuticals Shares Fall After 1-for-80 Reverse Stock Split Announcement	MT
Apr. 03	North American Morning Briefing : Powell Awaited -2-	DJ

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29
Prime Medicine Names Foghorn Therapeutics' CFO to be its New Finance Chief	Jan. 05
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
Vicore Pharma's New CEO to Formally Take Office	23-09-08
Sweden’s Hansa Biopharma Appoints New Chief Scientific Officer	23-09-01
Pieris Pharmaceuticals Says Patient Dosing in Cancer Drug Trial Triggers Milestone Payment From Boston Pharmaceuticals	23-08-17
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Pieris to Cut 70% Workforce, Hires Advisor For Strategic Review; AstraZeneca to End R&D Deal	23-07-18
Pieris Pharmaceuticals to Explore Strategic Options	23-07-18
Pieris Pharmaceuticals, Inc. Announces Executive Changes	23-07-13
Sector Update: Health Care Stocks Steady to Higher Late Wednesday	23-06-21
Sector Update: Health Care	23-06-21
Top Midday Decliners	23-06-21
Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday	23-06-21
Sector Update: Health Care	23-06-21
Pieris Pharmaceuticals Says AstraZeneca to Discontinue Phase 2a Trial of Asthma Treatment; Pieris Shares Fall Pre-Bell	23-06-21
Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference	23-05-21
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10
Pieris Pharmaceuticals, Inc. Announces Successful Completion of Safety Review for 10 Mg Dose of Phase 2A Trial of Elarekibep (Prs-060/Azd1402)	23-05-04
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Pieris Pharmaceuticals, Inc.

Equities

PIRS

US7207952026

Other languages

Filters